Loading...
Avecho Biotechnology Limited
AVE.AX•ASX
Healthcare
Biotechnology
A$0.006
A$0.00(0.00%)

Over the last four quarters, Avecho Biotechnology Limited achieved steady financial progress, growing revenue from $371021.00 in Q4 2022 to $312187.00 in Q2 2024. Gross profit stayed firm with margins at 66% in Q2 2024 versus 36% in Q4 2022. Operating income totaled -$2.89M in Q2 2024, maintaining a -927% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$2.62M. Net income dropped to -$2.18M, with EPS at -$0.001. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan